Shire PLC (SHPG) Position Increased by Quantbot Technologies LP
Quantbot Technologies LP boosted its stake in Shire PLC (NASDAQ:SHPG) by 925.0% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,732 shares of the biopharmaceutical company’s stock after acquiring an additional 9,685 shares during the period. Quantbot Technologies LP’s holdings in Shire PLC were worth $1,773,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds also recently bought and sold shares of the stock. Inspirion Wealth Advisors LLC raised its holdings in Shire PLC by 0.4% in the second quarter. Inspirion Wealth Advisors LLC now owns 1,944 shares of the biopharmaceutical company’s stock valued at $321,000 after acquiring an additional 8 shares in the last quarter. Synovus Financial Corp raised its holdings in Shire PLC by 0.4% in the second quarter. Synovus Financial Corp now owns 2,780 shares of the biopharmaceutical company’s stock valued at $458,000 after acquiring an additional 11 shares in the last quarter. Level Four Advisory Services LLC raised its holdings in Shire PLC by 0.5% in the first quarter. Level Four Advisory Services LLC now owns 2,745 shares of the biopharmaceutical company’s stock valued at $480,000 after acquiring an additional 13 shares in the last quarter. Baldwin Investment Management LLC raised its holdings in Shire PLC by 1.4% in the second quarter. Baldwin Investment Management LLC now owns 1,626 shares of the biopharmaceutical company’s stock valued at $269,000 after acquiring an additional 23 shares in the last quarter. Finally, Hartford Financial Management Inc. increased its stake in Shire PLC by 5.4% during the second quarter. Hartford Financial Management Inc. now owns 621 shares of the biopharmaceutical company’s stock valued at $102,000 after purchasing an additional 32 shares during the last quarter. 19.28% of the stock is currently owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: This piece was published by Daily Political and is the sole property of of Daily Political. If you are reading this piece on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be accessed at https://www.dailypolitical.com/2017/09/24/shire-plc-shpg-position-increased-by-quantbot-technologies-lp.html.
Shire PLC (NASDAQ SHPG) opened at 155.09 on Friday. Shire PLC has a 12 month low of $139.36 and a 12 month high of $206.94.
Shire PLC (NASDAQ:SHPG) last issued its quarterly earnings data on Friday, October 27th. The biopharmaceutical company reported $3.37 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $3.66 by ($0.29). Shire PLC had a net margin of 4.70% and a return on equity of 14.10%. Equities analysts predict that Shire PLC will post $14.93 earnings per share for the current year.
The business also recently disclosed a semiannual dividend, which will be paid on Friday, October 20th. Shareholders of record on Friday, September 8th will be issued a dividend of $0.1527 per share. The ex-dividend date of this dividend is Thursday, September 7th. This represents a dividend yield of 0.21%. Shire PLC’s payout ratio is presently 41.07%.
Several research firms have weighed in on SHPG. BidaskClub upgraded shares of Shire PLC from a “strong sell” rating to a “sell” rating in a research note on Friday, June 23rd. ValuEngine lowered shares of Shire PLC from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd. Cowen and Company reiterated an “outperform” rating and set a $325.00 target price on shares of Shire PLC in a research note on Wednesday, May 31st. Liberum Capital lowered shares of Shire PLC from a “buy” rating to a “hold” rating in a research note on Thursday, June 1st. Finally, HSBC Holdings plc upgraded shares of Shire PLC from a “reduce” rating to a “hold” rating in a research note on Thursday, July 6th. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating and fourteen have issued a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $220.08.
About Shire PLC
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.